Total Payments
$781.28
2024 Payments
$401.58
Companies
11
Transactions
28
Medicare Patients
5,914
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$748.55 (95.8%)
Education$32.73 (4.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $748.55 | 26 | 95.8% |
| Education | $32.73 | 2 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $217.42 | 7 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $189.46 | 5 | $0 (2024) |
| LeMaitre Vascular, Inc. | $90.95 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $74.79 | 3 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $57.97 | 3 | $0 (2024) |
| Amgen Inc. | $42.87 | 2 | $0 (2024) |
| Vifor Pharma, Inc. | $34.78 | 2 | $0 (2024) |
| Travere Therapeutics, Inc. | $30.32 | 2 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $15.84 | 1 | $0 (2017) |
| AKEBIA THERAPEUTICS INC | $13.81 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $401.58 | 18 | LeMaitre Vascular, Inc. ($90.95) |
| 2023 | $225.05 | 7 | Bayer Healthcare Pharmaceuticals Inc. ($150.11) |
| 2022 | $125.00 | 1 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2020 | $13.81 | 1 | AKEBIA THERAPEUTICS INC ($13.81) |
| 2017 | $15.84 | 1 | AMAG Pharmaceuticals, Inc. ($15.84) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $13.24 | General |
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/09/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/17/2024 | LeMaitre Vascular, Inc. | ARTEGRAFT VASCULAR GRAFT (Device) | Food and Beverage | Cash or cash equivalent | $90.95 | General |
| Category: ARTEGRAFT | ||||||
| 09/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Cardio-renal | ||||||
| 09/04/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Hyperkalemia | ||||||
| 08/30/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Nephrology | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/16/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/30/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 04/30/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $13.43 | General |
| 04/23/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $28.01 | General |
| 03/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Cardio-renal | ||||||
| 02/27/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Phosphate binder for ESRD | ||||||
| 01/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/24/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $33.54 | General |
| 12/05/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Cardio-renal | ||||||
| 11/08/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $27.54 | General |
| Category: Inflammation | ||||||
| 10/19/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Hyperkalemia | ||||||
| 10/17/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/05/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $13.07 | General |
| 08/03/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $120.49 | General |
| Category: Cardio-renal | ||||||
| 06/06/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,417 | 2,713 | $629,245 | $278,473 |
| 2022 | 17 | 1,439 | 2,907 | $642,655 | $281,892 |
| 2021 | 16 | 1,438 | 2,700 | $589,310 | $271,682 |
| 2020 | 17 | 1,620 | 3,297 | $812,062 | $317,025 |
Total Patients
5,914
Total Services
11,617
Medicare Billing
$1.1M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 239 | 550 | $93,500 | $53,844 | 57.6% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 18 | 141 | $105,750 | $41,335 | 39.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 282 | 627 | $81,510 | $41,098 | 50.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 210 | 224 | $78,400 | $31,207 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 146 | 342 | $68,400 | $27,519 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 86 | 171 | $47,025 | $17,960 | 38.2% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2023 | 83 | 200 | $46,000 | $16,671 | 36.2% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 56 | 80 | $17,600 | $9,887 | 56.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 61 | 82 | $12,300 | $7,174 | 58.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 12 | 25 | $18,750 | $6,129 | 32.7% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Office | 2023 | 45 | 47 | $11,515 | $5,100 | 44.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 40 | $10,400 | $4,230 | 40.7% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 49 | 68 | $10,880 | $4,037 | 37.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $6,900 | $3,680 | 53.3% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 20 | 21 | $6,615 | $3,195 | 48.3% |
| 90947 | Dialysis procedure requiring repeat evaluation | Facility | 2023 | 11 | 20 | $5,400 | $2,032 | 37.6% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 15 | 27 | $5,130 | $1,929 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $2,750 | $1,404 | 51.1% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 14 | 14 | $420.00 | $43.54 | 10.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 281 | 736 | $125,120 | $62,699 | 50.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 22 | 153 | $114,750 | $45,407 | 39.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 339 | 745 | $96,850 | $44,435 | 45.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 235 | 252 | $88,200 | $41,404 | 46.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 127 | 318 | $63,600 | $23,801 | 37.4% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2022 | 77 | 162 | $37,260 | $14,203 | 38.1% |
About Dr. Nitin Behl, M.D
Dr. Nitin Behl, M.D is a Internal Medicine healthcare provider based in Northfield, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2011. The National Provider Identifier (NPI) number assigned to this provider is 1235423807.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nitin Behl, M.D has received a total of $781.28 in payments from pharmaceutical and medical device companies, with $401.58 received in 2024. These payments were reported across 28 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($748.55).
As a Medicare-enrolled provider, Behl has provided services to 5,914 Medicare beneficiaries, totaling 11,617 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Northfield, NJ
- Active Since 06/01/2011
- Last Updated 02/17/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1235423807
Products in Payments
- Kerendia (Drug) $189.46
- LOKELMA (Drug) $154.35
- ARTEGRAFT VASCULAR GRAFT (Device) $90.95
- FARXIGA (Drug) $63.07
- Velphoro (Drug) $57.97
- Veltassa (Drug) $34.78
- TAVNEOS (Drug) $27.54
- FERAHEME (Drug) $15.84
- Aranesp (Biological) $15.33
- AURYXIA (Drug) $13.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Northfield
Samuel Moltz, M.d, M.D
Internal Medicine — Payments: $43,115
Internal Medicine $43,115
Robert Mathews, Md, MD
Internal Medicine — Payments: $6,094
Internal Medicine $6,094
Dr. Ulices Perez Feliz, Md, MD
Internal Medicine — Payments: $5,482
Internal Medicine $5,482
Dr. Steven Wolfman, D.o, D.O
Internal Medicine — Payments: $3,169
Internal Medicine $3,169
Maria Jimenez Cerna, M.d, M.D
Internal Medicine — Payments: $2,311
Internal Medicine $2,311
Behdokht Daneshvar, Md, MD
Internal Medicine — Payments: $645.12
Internal Medicine $645.12